LoginSignup
Johnson&Johnson logo

Johnson&Johnson

Stock
Stock
ISIN: US4781601046
Ticker: JNJ
US4781601046
JNJ

Price

Price

Historical dividends and forecast

All dividend data

Johnson&Johnson has so far distributed $3.67 in 2024. The next dividend will be paid on 10.12.2024

$1.449

CHART BY

Frequently asked questions

What is Johnson&Johnson's market capitalization?

The market capitalization of Johnson&Johnson is $372.70B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is Johnson&Johnson's Price-to-Earnings (P/E) ratio?

The Price-to-Earnings (P/E) ratio (TTM) for Johnson&Johnson is 25.59. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.

What is the Earnings Per Share (EPS) for Johnson&Johnson?

Johnson&Johnson's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $6.049. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Johnson&Johnson's stock?

Currently, 24 analysts cover Johnson&Johnson's stock, with a consensus target price of $172.71. Analyst ratings provide insights into the stock's expected performance.

What is Johnson&Johnson's revenue over the trailing twelve months?

Over the trailing twelve months, Johnson&Johnson reported a revenue of $87.70B.

Is Johnson&Johnson paying dividends?

Yes, Johnson&Johnson is paying dividends. The next payment is scheduled for 10.12.2024, with an expected amount of .

What is the EBITDA for Johnson&Johnson?

Johnson&Johnson's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $31.77B. EBITDA measures the company's overall financial performance.

What is the free cash flow of Johnson&Johnson?

Johnson&Johnson has a free cash flow of $9.04B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Johnson&Johnson's stock?

The 5-year beta for Johnson&Johnson is 0.49. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Johnson&Johnson have, and what sector and industry does it belong to?

Johnson&Johnson employs approximately 131,900 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Johnson&Johnson's shares?

The free float of Johnson&Johnson is 2.41B. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $372.70B

5Y beta

 0.49

EPS (TTM)

 $6.049

Free Float

 2.41B

P/E ratio (TTM)

 25.59

Revenue (TTM)

 $87.70B

EBITDA (TTM)

 $31.77B

Free Cashflow (TTM)

 $9.04B

Pricing

1D span
$153.16$155.11
52W span
$143.13$168.85

Analyst Ratings

The price target is $172.71 and the stock is covered by 24 analysts.

Buy

12

Hold

12

Sell

0

Information

Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, cardiovascular intervention, and vision fields. The MedTech segment also offers a commercially available intravascular lithotripsy (IVL) platform for coronary artery disease (CAD) and peripheral artery disease (PAD).

131,900

Biotechnology & Drugs

Health Care

Identifier

ISIN

US4781601046

Primary Ticker

JNJ

Knockouts

Join the conversation
Sign upLogin